Evidence review
Evidence Specific to Compounded Tirzepatide
There is no randomised controlled trial of any compounded tirzepatide product. Every efficacy and safety figure in circulation belongs to the FDA-approved product studied in SURMOUNT and SURPASS. Compounded versions may contain the same active molecule, but formulation, concentration, excipients, and quality control differ and have never been tested for equivalence.
Key takeaways
- No randomised trial has evaluated a compounded tirzepatide product's efficacy or safety.
- All cited efficacy figures belong to the approved product, not to compounded versions.
- Formulation, concentration, and excipients can differ between compounded preparations.
- Absence of trials is not proof of harm — but it is a real and unresolved evidence gap.
- Adverse-event reporting for compounded products is less systematic than for approved drugs.
| Randomised trials of compounded tirzepatide | None identified |
|---|---|
| Source of all efficacy figures | FDA-approved product (SURMOUNT / SURPASS) |
| Known variables | Concentration, excipients, salt or base form, sterility, beyond-use dating |
| Regulatory status | Not FDA approved; not reviewed for safety, effectiveness, or quality |
| Adverse-event capture | Less systematic than for approved products |
What can the approved-product trials actually support?
What the evidence shows
- Tirzepatide, as manufactured and studied, produces large mean weight reduction at labelled doses.
- The molecule's mechanism (dual GIP/GLP-1 receptor agonism) is well characterised.
- Safety signals in labelling derive from systematic trial adverse-event collection.
What the evidence does not show
- That a compounded preparation delivers equivalent exposure or effect.
- That compounded concentration matches the label of the approved product.
- That adverse events from compounded products are captured at comparable rates.
- That an oral, sublingual, ODT, or troche compounded form is absorbed comparably to an injection.
Why does formulation matter if the molecule is the same?
Because a peptide drug's effect depends on how much intact drug reaches the circulation, and that depends on concentration accuracy, excipients, pH, storage stability, and sterility — all of which are controlled and verified for an approved product and are not independently verified for a compounded one. Two vials can contain the same nominal molecule and deliver materially different exposure.
Is absence of evidence the same as evidence of harm?
No, and it is important not to overclaim in either direction. Many people use compounded products without reported incident. What the absence of trials means is narrower and still important: nobody can quantify how a compounded product performs, because the study that would quantify it does not exist. Decisions get made under genuine uncertainty.
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
| Series | Wk 0 | Wk 12 | Wk 24 | Wk 40 | Wk 56 | Wk 72 |
|---|---|---|---|---|---|---|
| Tirzepatide 15 mg | 0% | -6.5% | -12.4% | -16.8% | -19.3% | -20.9% |
| Tirzepatide 5 mg | 0% | -5.1% | -9.3% | -12.4% | -14.2% | -15.0% |
| Placebo | 0% | -1.4% | -2.3% | -2.8% | -3.0% | -3.1% |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
What does this page cover, and what does it deliberately leave out?
This page addresses Clinical data, adverse events and formulation variability and gaps, organised around the primary question of compounded tirzepatide evidence. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Clinical data | Covered on this page | Primary evidence |
| Adverse events | Covered on this page | Primary evidence |
| Formulation variability and gaps | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with the registered protocol and the peer-reviewed publication |
What are the limits of what this page can tell you?
Every page on this site rests on a specific primary trial record, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the registered protocol and the peer-reviewed publication.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on compounded tirzepatide evidence.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 8 technical terms this page uses, including 503A, 503B, GIP, GLP-1 — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| GIP | Glucose-dependent insulinotropic polypeptide. An incretin hormone released by the small intestine after eating. Tirzepatide activates its receptor alongside the GLP-1 receptor, which is the feature that distinguishes it from single-agonist drugs such as semaglutide. |
| GLP-1 | Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| excipient | An inactive ingredient in a formulation. Excipients affect stability, tolerability, and injection-site reactions, and can differ between compounded preparations and the approved product. |
| placebo | An inactive comparator given so that the effect of the drug can be separated from the effect of being in a trial. Placebo groups in the SURMOUNT trials still lost some weight, which is why the placebo-subtracted difference matters more than the raw figure. |
| randomised controlled trial | A study in which participants are assigned to treatment or comparator by chance. Randomisation is what allows a difference in outcome to be attributed to the treatment rather than to differences between the groups. |
Frequently asked questions
Is there any clinical trial of compounded tirzepatide?
No randomised trial of a compounded tirzepatide product has been identified.
Does approved-drug evidence apply to compounded versions?
Not automatically. Formulation, concentration, and quality control differ and have not been tested for equivalence.
Does that mean compounded tirzepatide does not work?
No. It means the effect has not been measured in a controlled study, so it cannot be quantified.
What can I check instead?
Pharmacy identity, state licensure, 503A versus 503B status, and whether concentration and beyond-use dating are disclosed.
Are adverse events tracked the same way?
No — reporting for compounded preparations is less systematic than for approved products.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.